Bristol-Myers Squibb Co (BMY) Expected to Post Quarterly Sales of $5.19 Billion

Brokerages expect Bristol-Myers Squibb Co (NYSE:BMY) to announce $5.19 billion in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Bristol-Myers Squibb’s earnings, with the lowest sales estimate coming in at $5.13 billion and the highest estimate coming in at $5.28 billion. Bristol-Myers Squibb reported sales of $4.93 billion in the same quarter last year, which indicates a positive year over year growth rate of 5.3%. The company is scheduled to announce its next quarterly earnings results on Thursday, April 26th.

According to Zacks, analysts expect that Bristol-Myers Squibb will report full-year sales of $5.19 billion for the current fiscal year, with estimates ranging from $20.86 billion to $21.86 billion. For the next financial year, analysts anticipate that the company will post sales of $23.38 billion per share, with estimates ranging from $21.97 billion to $24.58 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Bristol-Myers Squibb.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share.

A number of equities analysts recently commented on BMY shares. Credit Suisse Group restated a “hold” rating and set a $61.00 target price (up previously from $58.00) on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Piper Jaffray Companies restated a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a report on Friday, October 27th. Leerink Swann upped their target price on Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, January 19th. Finally, Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research note on Thursday. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $65.58.

In other news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after acquiring an additional 333,685 shares during the last quarter. BlackRock Inc. grew its stake in shares of Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after acquiring an additional 2,367,864 shares during the last quarter. Dodge & Cox boosted its position in shares of Bristol-Myers Squibb by 1.6% during the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after buying an additional 459,271 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Bristol-Myers Squibb by 16.2% during the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after buying an additional 3,735,453 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of Bristol-Myers Squibb by 3.9% during the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after buying an additional 910,496 shares during the last quarter. 69.70% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb (BMY) opened at $62.63 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The company has a market capitalization of $99,675.04, a P/E ratio of 106.15, a P/E/G ratio of 1.92 and a beta of 1.09. Bristol-Myers Squibb has a twelve month low of $51.12 and a twelve month high of $66.10.

The company also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.55%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.

TRADEMARK VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Expected to Post Quarterly Sales of $5.19 Billion” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://weekherald.com/2018/02/15/bristol-myers-squibb-co-bmy-expected-to-post-quarterly-sales-of-5-19-billion.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply